GCSF Reduces Inflammation in ALS Mouse Model
Author Information
Author(s): Pollari Eveliina, Savchenko Ekaterina, Jaronen Merja, Kanninen Katja, Malm Tarja, Wojciechowski Sara, Ahtoniemi Toni, Goldsteins Gundars, Giniatullina Raisa, Giniatullin Rashid, Koistinaho Jari, Magga Johanna
Primary Institution: University of Eastern Finland
Hypothesis
Is pegfilgrastim, a sustained-action GCSF, protective in a mouse model of amyotrophic lateral sclerosis (ALS)?
Conclusion
GCSF attenuated inflammation in the CNS and the periphery in a mouse model of ALS and thereby delayed the progression of the disease.
Supporting Evidence
- Long-term pegfilgrastim treatment prolonged mutant SOD1 mice survival.
- Pegfilgrastim treatment reduced the production of pro-inflammatory cytokines.
- GCSF treatment decreased inflammation in the spinal cord.
- Pegfilgrastim increased the number of anti-inflammatory monocytes in the bone marrow and spleen.
Takeaway
This study found that a treatment called GCSF can help reduce inflammation in mice with a disease similar to ALS, which may help them live longer.
Methodology
Mutant SOD1 mice were treated with pegfilgrastim starting at the presymptomatic stage and continued until the end stage, with assessments of inflammation and survival.
Potential Biases
Potential bias in the interpretation of results due to the use of a single animal model.
Limitations
The study primarily used a mouse model, which may not fully replicate human ALS conditions.
Participant Demographics
Male SOD1 G93A mice were used for the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website